This review provides an updated overview of the management of metastatic colorectal cancer (CRC). With widespread application of personalized therapy based on specific patient and tumor characteristics, this will enable the oncologists to optimize overall survival while maintaining quality of life. The role of k-ras and braf testing in helping select systemic therapy that includes cetuximab or bevacizumab is clarified. Current management of metastatic CRC is based on careful attention to these finer points, explained in this article.
No takes yet. Share an insight, caveat, or question.
Satya Dattatreya (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: